HCPLive

The latest edition of The Provider's Digest, HCPLive's monthly newsletter spotlighting regulatory decisions and pipeline news, is now live! In our February 2025 recap, we spotlight 8 FDA regulatory decisions, including 7 approvals or clearances and 1 Refusal to File letter. Be sure to subscribe for a recap of the therapies, companies, and individuals moving the needle in healthcare during the past month, delivered on the first Saturday of each new month!

Healthcare experts M. Bradley Drummond, MD, MHS, MeiLan K. Han, MD, MS, Emily Wan, MD MPH, and Ravi Kalhan, MD, MS discuss COPD and unmet needs in its treatment in our peer-to-peer panel discussion. During this engaging session, they also discuss clinical evidence for novel agents and important updates to the 2025 GOLD COPD Guidelines. Watch now https://bit.ly/407rOHV

AstraZeneca and Alexion Pharmaceuticals, Inc. announced eneboparatide (AZP-3601) met the primary endpoint at 24 weeks in the Phase 3 CALYPSO trial, normalizing serum calcium levels with statistical significance in adults with?chronic hypoparathyroidism. ?? https://lnkd.in/eWx5RW2R #Endocrinology #RareDisease #PipelineNews

Tandem Diabetes Care just announced the launch of the Control-IQ+ automated insulin delivery (AID) technology, with an expanded indication for people with type 1 diabetes aged 2 years and older and adults with type 2 diabetes. On the latest episode of #DiabetesDialogue, hosts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP, BC-ADM, CDCES, spoke with Laurel Messer, PhD, RN, CDCES, BC-ADM, on key enhancements in the Control-IQ+ algorithm, including a broader weight range, temp basal adjustments, an extended bolus option, and AutoBolus corrections—advancements designed to improve flexibility, personalization, and outcomes in diabetes management. ?? https://lnkd.in/eBeEQnYB #DiabetesCare #Podcast

Have you seen the live recording of The Medical Sisterhood: Empower Hour, filmed at the 2025 American Academy of Dermatology Annual Meeting? A conversation between Mona Shahriari, MD, FAAD and Drs. Latanya Benjamin, MD, FAAD, FAAP and Lindsay Ackerman, MD, FAAD covered a variety of notable topics, including advocacy, embracing discomfort, and the 3 speakers’ own journeys in medicine. Check it out here: https://lnkd.in/eRxhZ2yn #Dermatology #MedicalSisterhood?

Join us on Cushing’s Awareness Day for a live national broadcast focused on identifying and screening for hypercortisolism. Experts will share insights on its impact on patient outcomes, the challenges of delayed diagnosis, and how it affects chronic disease management. Our expert panel will discuss key clinical presentations, patient subtypes that may benefit from screening, and the role of commonly used screening tests in clinical practice. Do not miss this opportunity to enhance your understanding and improve patient care. Register Today: https://bit.ly/41tjGRE #CushingsAwareness #Hypercortisolism #Endocrinology

?? AAD 2025: Breaking Down 7 Major Phase 3 Trials ?? #AAD2025 Annual Meeting showcased groundbreaking phase 3 data that could reshape dermatology treatment in the near future. Here’s a quick recap of 7 key trials: ? Ruxolitinib Cream – Rapid itch relief in prurigo nodularis from Incyte (TRuE-PN) ? Icotrokinra – A first-in-class oral option for plaque psoriasis from Johnson & Johnson (ICONIC-LEAD) ? Ivarmacitinib – JAK1 inhibitor from shows promise for severe alopecia areata ? Rocatinlimab – T-cell rebalancing therapy for atopic dermatitis from Amgen and Kyowa Kirin (ROCKET-Horizon) ? Dupilumab – Breakthrough results in bullous pemphigoid for Regeneron and Sanofi (LIBERTY-BP ADEPT) ? Baricitinib – Hair regrowth in pediatric alopecia areata for Eli Lilly and Company (BRAVE-AA-PEDS) ? Deucravacitinib – Promising results in psoriatic arthritis for Bristol Myers Squibb (POETYK PsA-2) Get the full breakdown and links to expert insights, exclusively on HCPLive: https://lnkd.in/eWyBNVtK

As the supply of GLP-1 receptor agonists stabilizes, competition over pricing and access is intensifying—both among manufacturers and in the regulatory landscape. ?? Eli Lilly and Company expanded its LillyDirect program and introduced the Zepbound Self Pay Journey Program, offering reduced-cost vials to improve affordability. ???Novo Nordisk launched NovoCare Pharmacy, a direct-to-patient delivery service that lowers the cash price of Wegovy to $499 per month. With insurers still reluctant to provide broad coverage for obesity treatment, these pricing strategies could have a significant impact on patient access. On this episode of #DiabetesDialogue, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP, BC-ADM, CDCES discuss what these latest developments mean for both clinicians and patients. https://lnkd.in/eW_Mge4n

The FDA has accepted the supplemental New Drug Application (sNDA) for finerenone (KERENDIA; Bayer) targeting the treatment of adults with?heart failure with an LVEF of ≥40%, including HFmrEF and HFpEF. Submission was based on positive data from the Phase III FINEARTS-HF trial, showing a statistically significant 16% reduction in the composite of CV death and total HF events. ?? https://lnkd.in/gxYjajy3 #FDANews #Pipeline #HeartFailure #Cardiology

New research from Leigh Anne Dageforde, MD, MPH, of Massachusetts General Hospital and Harvard Medical School, highlights key challenges in managing alcohol use disorder (AUD) post-liver transplant for patients with alcohol-associated liver disease and severe alcohol-associated hepatitis. Despite a surge in liver transplants for these conditions, most centers have yet to adapt their practices to better support this growing patient population. Read more: https://lnkd.in/eZYCJpU6